These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2595664)

  • 1. The incidence and clinical significance of amiodarone and acenocoumarol interaction.
    Caraco Y; Chajek-Shaul T
    Thromb Haemost; 1989 Nov; 62(3):906-8. PubMed ID: 2595664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prolonged diminished effect of coumarin derivatives after use of rifampicin].
    Harmsze AM; Deneer VH; Wiltink EH
    Ned Tijdschr Geneeskd; 2007 Sep; 151(35):1945-9. PubMed ID: 17907547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
    Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
    Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients who take uneven doses of acenocoumarol exhibit significant fluctuating levels of anticoagulation.
    Marco F; Gutiérrez JI; Orkolaga K; Márquez JA; Ojínaga MJ; de Zárate IO; de Heredia JM
    Blood Coagul Fibrinolysis; 2006 Sep; 17(6):509-12. PubMed ID: 16905959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potentiation of acenocoumarol anticoagulant effect by amiodarone.
    Arboix M; Frati ME; Laporte JR
    Br J Clin Pharmacol; 1984 Sep; 18(3):355-60. PubMed ID: 6487475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of the potentiation of acenocoumarol by amiodarone.
    Richard C; Riou B; Berdeaux A; Fournier C; Khayat D; Rimailho A; Giudicelli JF; Auzépy P
    Eur J Clin Pharmacol; 1985; 28(6):625-9. PubMed ID: 4065185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial.
    Ageno W; Crowther M; Steidl L; Ultori C; Mera V; Dentali F; Squizzato A; Marchesi C; Venco A
    Thromb Haemost; 2002 Jul; 88(1):48-51. PubMed ID: 12152676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
    Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
    Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced anticoagulant effect of acenocoumarol induced by amiodarone coadministration.
    Caraco Y; Raveh D; Flugelman M; Raz I
    Isr J Med Sci; 1988 Nov; 24(11):688-9. PubMed ID: 3215763
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosuvastatin-acenocoumarol interaction.
    Mondillo S; Ballo P; Galderisi M
    Clin Ther; 2005 Jun; 27(6):782-4. PubMed ID: 16117985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).
    Cosmi B; Palareti G; Carpanedo M; Pengo V; Biasiolo A; Rampazzo P; Morstabilini G; Testa S
    Haematologica; 2000 Aug; 85(8):826-31. PubMed ID: 10942929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term drug interaction of warfarin with amiodarone].
    Hirmerová J; Suchý D; Mádr T
    Cas Lek Cesk; 2003 Jan; 142(1):39-42. PubMed ID: 12693297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence, magnitude, and time course of the amiodarone-warfarin interaction.
    Kerin NZ; Blevins RD; Goldman L; Faitel K; Rubenfire M
    Arch Intern Med; 1988 Aug; 148(8):1779-81. PubMed ID: 3401099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.
    Wey PF; Petitjeans F; Lions C; Ould-Ahmed M; Escarment J
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):173-7. PubMed ID: 18775393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Digoxin-amiodarone interaction].
    Strocchi E; Malini PL; Graziani A; Ambrosioni E; Magnani B
    G Ital Cardiol; 1984 Jan; 14(1):12-5. PubMed ID: 6706051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements.
    van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM
    Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plasma concentrations and amiodarone/desethylamiodarone relations in patients subjected to chronic treatment].
    Ortiz M; Gaete L; Asenjo R; Fernández F; Saavedra I
    Rev Med Chil; 1996 Jan; 124(1):77-82. PubMed ID: 8762622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.